Academic Journal
Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV-1 Reverse Transcriptase.
| Τίτλος: | Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV-1 Reverse Transcriptase. |
|---|---|
| Συγγραφείς: | da Silva Moura JA; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., de Melo MVG; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., do Nascimento DRS; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., Bezerra TPW; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., Métifiot M; UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, CNRS, Bordeaux, France., Recordon-Pinson P; UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, CNRS, Bordeaux, France., da Rocha Pitta MG; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., da Rocha Pitta MG; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., Pereira MC; Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brazil., Andreola ML; UMR 5234, Microbiologie Fondamentale et Pathogénicité, Université de Bordeaux, CNRS, Bordeaux, France. |
| Πηγή: | ChemMedChem [ChemMedChem] 2026 Oct 14; Vol. 21 (19), pp. e70494. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101259013 Publication Model: Print Cited Medium: Internet ISSN: 1860-7187 (Electronic) Linking ISSN: 18607179 NLM ISO Abbreviation: ChemMedChem Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Weinheim, Germany : Wiley-VCH, c2006- |
| Ιατρικοί όροι (MeSH): | HIV Reverse Transcriptase*/antagonists & inhibitors , HIV Reverse Transcriptase*/metabolism , Reverse Transcriptase Inhibitors*/chemistry , Reverse Transcriptase Inhibitors*/pharmacology , Reverse Transcriptase Inhibitors*/chemical synthesis , Thiazoles*/chemistry , Thiazoles*/pharmacology , Thiazoles*/chemical synthesis , HIV-1*/drug effects , HIV-1*/enzymology , Thiazolidines*/chemistry , Thiazolidines*/pharmacology , Thiazolidines*/chemical synthesis , Anti-HIV Agents*/chemistry , Anti-HIV Agents*/pharmacology , Anti-HIV Agents*/chemical synthesis , Drug Design*, Humans ; Structure-Activity Relationship ; Chemistry, Pharmaceutical |
| Περίληψη: | The therapy to treat the Human Immunodeficiency virus (HIV) and decrease the viral load has been a challenge since its discovery due to its ability to mutate, escape from drug therapies, and immunologic system. Consequently, the development of new therapies, especially potential molecules that focus on specific viral mechanisms to block viral replication, became a critical challenge in recent decades. The Reverse Transcriptase (RT) is an RNA- and DNA-dependent DNA polymerase enzyme that is responsible for transcribing viral RNA into double-stranded DNA. Non-nucleoside RT Inhibitors perform important role in HIV therapy, and they are responsible for inhibiting RT by blocking its allosteric site, which shows physico-chemical properties such as high hydrophobicity and key amino acid-to-hydrogen bond interactions. For this reason, designing new molecules with innovative heterocycles compatible with these characteristics can provide new potential inhibitors. For example, pentacyclic heterocycles like thiazole and its derivatives like thiazolidinedione, which have physico-chemical properties that can interact with the allosteric site of RT, can be a new perspective in designing new Non-nucleoside RT Inhibitors. This work reviews the scientific literature concerning these compounds and can help the design of new antiviral therapeutics. (© 2026 The Author(s). ChemMedChem published by Wiley‐VCH GmbH.) |
| References: | R. J. Landovitz, H. Scott, and S. G. Deeks, “Prevention, Treatment and Cure of HIV Infection,” Nature Reviews Microbiology 21 (2023): 657–670. L.‐G. Bekker, M. Das, Q. A. Karim, et al., “Twice‐Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women,” New England Journal of Medicine 391 (2024): 1179–1192. F. Amblard, D. Patel, E. Michailidis, et al., “HIV Nucleoside Reverse Transcriptase Inhibitors,” European Journal of Medicinal Chemistry 240 (2022): 114554. Abacavir, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB01048. Tenofovir, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB14126. Entecavir, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00442. Lamivudine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00709. Emtricitabine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00879. Zidovudine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00495. Nevirapine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00238. Delavirdine, n.d., acessed June 23, 2025, https://go.drugbank.com/drugs/DB00705. Efavirenz, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00625. Doravirine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB12301. Rilpivirine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB08864. Etravirine, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB06414. M. Vanangamudi, S. Kurup, and V. Namasivayam, “Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): A Brief Overview of Clinically Approved Drugs and Combination Regimens,” Current Opinion in Pharmacology 54 (2020): 179–187. K. Łupina, K. Nowak, D. Lorek, et al., “Pharmacological Advances in HIV Treatment: From ART to Long‐Acting Injectable Therapies,” Archives of Virology 170 (2025): 195. P. Mundlia, A. Sharma, J. Kaur, et al., “From Antiretrovirals to Curative Therapies: Current Developments in HIV Treatment and Prevention,” European Journal of Medicinal Chemistry 300 (2025): 118190. A. Buzibye, K. Wools‐Kaloustian, A. Olagunju, et al., “Relating CYP2B6 Genotype and Efavirenz Resistance Among Post‐Partum Women Living With HIV With High Viremia in Uganda: A Nested Cross‐Sectional Study,” AIDS Research and Therapy 20 (2023): 20. J. M. Humphrey, S. M. Ali, A. DeLong, et al., “HIV Drug Resistance, Early Treatment Outcomes and Impact of Guidelines Compliance After Protease Inhibitor‐Based Second‐Line Failure in a Dedicated Resistance Clinic in Western Kenya: A Retrospective Cohort Study,” Journal of the International AIDS Society 28 (2025): e26523. C. Efeoglu, S. Taskin, O. Selcuk, et al., “Synthesis, Anti‐Inflammatory Activity, Inverse Molecular Docking, and Acid Dissociation Constants of New Naphthoquinone‐Thiazole Hybrids,” Bioorganic & Medicinal Chemistry 95 (2023): 117510. J. Guo, Z. Xie, W. Ruan, Q. Tang, D. Qiao, and W. Zhu, “Thiazole‐Based Analogues as Potential Antibacterial Agents Against Methicillin‐Resistant Staphylococcus aureus (MRSA) and Their SAR Elucidation,” European Journal of Medicinal Chemistry 259 (2023): 115689. Z. Hao, B. Yu, W. Gao, et al., “Design, Synthesis and Fungicidal Activity of Pyrazole–thiazole Carboxamide Derivatives,” Molecular Diversity 26 (2022): 205–214. M. Musa, M. Bello, and E. C. Agwamba, “Synthesis, Molecular Docking, and Anticancer Screening of Ester‐Based Thiazole Derivatives,” Chemistry & Biodiversity 21 (2024): e202401159. A. V. Kurkin, F. Curreli, I. R. Iusupov, et al., “Design, Synthesis, and Antiviral Activity of the Thiazole Positional Isomers of a Potent HIV‐1 Entry Inhibitor NBD‐14270,” ChemMedChem 17 (2022): e202200344. Ritonavir, n.d., accessed June 23, 2025, https://go.drugbank.com/drugs/DB00503. M. A. Davidson, D. R. Mattison, L. Azoulay, and D. Krewski, “Thiazolidinedione Drugs in the Treatment of Type 2 diabetes Mellitus: Past, Present and Future,” Critical Reviews in Toxicology 48 (2018): 52–108. M. B. Cavalcanti, L. L. B. Leite, D. M. de Queiroz, et al., “Evaluation of the Action of LPSF/GQ‐16 on Cytokines and PPAR‐γ Gene Expression After In Vitro Irradiation of Peripheral Blood Mononuclear Cells,” International Journal of Radiation Biology 97 (2021): 1649–1656. O. A. Silva, H. V. Ribeiro‐Filho, T. M. Avelino, et al., “GQ‐130, a Novel Analogue of Thiazolidinedione, Improves Obesity‐Induced Metabolic Alterations in Rats: Evidence for the Involvement of PPARβ/δ Pathway,” Clinical and Experimental Pharmacology and Physiology 47 (2020): 798–808. A. R. de Almeida, A. T. Dantas, M. E. de Oliveira Gonçalves, et al., “PPARγ Partial Agonist LPSF/GQ‐16 Prevents Dermal and Pulmonary Fibrosis in HOCl‐Induced Systemic Sclerosis (SSc) and Modulates Cytokine Production in PBMC of SSc Patients,” Inflammopharmacology 32 (2024): 433–446. N. S. Sethi, D. N. Prasad, and R. K. Singh, “Synthesis, Anticancer, and Antibacterial Studies of Benzylidene Bearing 5‐Substituted and 3,5‐Disubstituted‐2,4‐Thiazolidinedione Derivatives,” Medicinal Chemistry 17 (2021): 369–379. S. M. C. Gonçalves, L. V. Galdino, M. C. Lima, et al., “Evaluation of Thiazolidine Derivatives With Potential Anti‐ZIKV Activity,” Current Topics in Medicinal Chemistry 24, no. 25 (2024): 2224–2237. I. L. R. de Oliveira, J. A. da S. Moura, P. Recordon‐Pinson, et al., “Novel Thiazolidinedione Derivatives as Potential ZIKV Antiviral Inhibitors,” Microorganisms 13 (2025): 1967, https://doi.org/10.3390/microorganisms13091967. H. M. Kasralikar, S. C. Jadhavar, S. V. Goswami, N. S. Kaminwar, and S. R. Bhusare, “Design, Synthesis and Molecular Docking of Pyrazolo [3,4d] Thiazole Hybrids as Potential Anti‐HIV‐1 NNRT Inhibitors,” Bioorganic Chemistry 86 (2019): 437–444. S. N. Sriharsha, N. Jainab, M. S. Biradar, et al., “Novel β‐L‐1,3‐Thiazolidine Pyrimidine Nucleoside Analogues: Design, Synthesis, Molecular Docking, and Anti‐HIV Activity,” Journal of Molecular Structure 1294 (2023): 136304. I. M. G. Andrade, E. O. Lima Filho, C. F. Valadão, L S. M. Forezi, and F. C. da Silva, “Recent Advances in Isatin–Thiazole Hybrids: Synthesis, Structural Design, and Biological Application,” Chemistry & Biodiversity 22 (2025): e01989. M. R. Buemi, R. Gitto, L. Ielo, C. Pannecouque, and L. De Luca, “Inhibition of HIV‐1 RT Activity by a New Series of 3‐(1,3,4‐Thiadiazol‐2‐yl)thiazolidin‐4‐One Derivatives,” Bioorganic & Medicinal Chemistry 28 (2020): 115431. A. Petrou, P. Eleftheriou, A. Geronikaki, M. G. Akrivou, and I. Vizirianakis, “Novel Thiazolidin‐4‐Ones as Potential Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase,” Molecules 24 (2019): 3821. A. V. Rivera, H. Donald, M. Alaoui‐El‐Azher, et al., “Discovery of Benzisothiazolone Derivatives as Bifunctional Inhibitors of HIV‐1 Reverse Transcriptase DNA Polymerase and Ribonuclease H Activities,” Biomolecules 14 (2024): 819. M. Fesatidou, A. Petrou, and A. Geronikaki, “Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS‐CoV‐2 Main Protease Inhibitors,” Chemistry & Biodiversity 21 (2024): e202401697. S. Singh, K. S. Srivastava, P. Gahtori, et al., “Design, and Synthesis of 2,4‐Thiazolidinedione Substituted 1,3,5‐Triazine Derivatives as Anti‐HIV Agent via Inhibition of Reverse Transcriptase Along With Anti‐SARS CoV‐2, Antibacterial and Antibiofilm Activity,” Bioorganic Chemistry 160 (2025): 108427. A. Corona, R. Meleddu, O. Delelis, et al., “5‐Nitro‐3‐(2‐(4‐Phenylthiazol‐2‐yl)hydrazineylidene)indolin‐2‐One Derivatives Inhibit HIV‐1 Replication by a Multitarget Mechanism of Action,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1193280, https://doi.org/10.3389/fcimb.2023.1193280. I. P. Singh, S. Gupta, and S. Kumar, “Thiazole Compounds as Antiviral Agents: An Update,” Medicinal Chemistry 16 (2020): 4–23. T. A. Farghaly, A. M. R. Alsaedi, N. A. Alenazi, and M. F. Harras, “Anti‐Viral Activity of Thiazole Derivatives: An Updated Patent Review,” Expert Opinion on Therapeutic Patents 32 (2022): 791–815. S. J. Kanchumarthy, G. Rasajna, G. Kamala, et al., “Current Advances in Synthesis and Therapeutic Applications of Thiazole and Its Derivatives: Review Article,” Journal of Pharma Insights and Research 2 (2024): 107–114. N. A. Ghafoor, K. K. Kırboğa, Ö. Baysal, B. E. Süzek, and R. S. Silme, “Data Mining and Molecular Dynamics Analysis to Detect HIV‐1 Reverse Transcriptase RNase H Activity Inhibitor,” Molecular Diversity 28 (2024): 1869–1888. J. Desantis, S. Massari, A. Corona, et al., “1,2,4‐Triazolo[1,5‐a]pyrimidines as a Novel Class of Inhibitors of the HIV‐1 Reverse Transcriptase‐Associated Ribonuclease H Activity,” Molecules 25 (2020): 1183. A. K. Singh and K. Das, “Insights Into HIV‐1 Reverse Transcriptase (RT) Inhibition and Drug Resistance From Thirty Years of Structural Studies,” Viruses 14 (2022): 1027. N. Bhardwaj, D. Choudhary, A. Pathania, S. Baranwal, and P. Kumar, “Synthesis and Molecular Docking Studies of Quinoline Derivatives as HIV Non‐Nucleoside Reverse Transcriptase Inhibitors,” Turkish Journal of Chemistry 44 (2020): 1623–1641. J. Park, N. Baruch‐Torres, and Y. W. Yin, “Structural and Molecular Basis for Mitochondrial DNA Replication and Transcription in Health and Antiviral Drug Toxicity,” Molecules 28 (2023): 1796. P. Chandra, S. Ganguly, P. K. Deb, and M. Ghosh, “Design of Novel Imidazole Derivatives as Potential Non‐Nucleoside Reverse Transcriptase Inhibitors Using Molecular Docking and Dynamics Strategies,” Current Pharmaceutical Design 31 (2024): 65–82, https://doi.org/10.2174/0113816128322984240725055333. P. Chandra, S. Swastika, and M. Ghosh. “In Silico Studies of Piperazinyl‐4‐Nitroimidazole Derivatives in the Non‐Nucleoside Inhibitory Binding Pocket of Human Immunodeficiency Virus‐1‐Reverse Transcriptase Enzyme,” Indian Journal of Heterocyclic Chemistry, 33, no. 03 (2023): 293, https://doi.org/10.59467/ijhc.2023.33.293. K.‐F. Chan, C. T.‐T. Su, A. Krah, et al., “An Alternative HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibition Mechanism: Targeting the p51 Subunit,” Molecules 25 (2020): 5902. R. M. Esnouf, J. Ren, A. L. Hopkins, et al., “Unique Features in the Structure of the Complex Between HIV‐1 Reverse Transcriptase and the Bis(heteroaryl)piperazine (BHAP) U‐90152 Explain Resistance Mutations for This Nonnucleoside Inhibitor,” Proceedings of the National Academy of Sciences 94 (1997): 3984–3989. R. P. D. Bank, n.d., “RCSB PDB ‐ 1KLM: HIV‐1 Reverse Transcriptase Complexed With BHAP U‐90152.” accessed June 23, 2025. https://www.rcsb.org/structure/1KLM. M. Yadav, R. Srivastava, F. Naaz, P. S. S. Gupta, S. K. Panda, and M. K. Rana, “Hydroxyalkynyl Uracil Derivatives as NNRTIs Against HIV‐1: In Silico Predictions, Synthesis, Docking and Molecular Dynamics Simulation Studies,” Journal of Biomolecular Structure and Dynamics 41 (2022): 8068–8080. P. A. Sánchez‐Murcia, S. De Castro, C. García‐Aparicio, et al., “Peptides Mimicking the β7/β8 Loop of HIV‐1 Reverse Transcriptase p51 as ‘Hotspot‐Targeted’ Dimerization Inhibitors,” ACS Medicinal Chemistry Letters 11 (2020): 811–817. A. Corona, E. Ballana, S. Distinto, et al., “Targeting HIV‐1 RNase H: N’‐(2‐Hydroxy‐Benzylidene)‐3,4,5‐Trihydroxybenzoylhydrazone as Selective Inhibitor Active Against NNRTIs‐Resistant Variants,” Viruses 12 (2020): 729. T. Ilina, K. LaBarge, S. G. Sarafianos, R. Ishima, and M. A. Parniak, “Inhibitors of HIV‐1 Reverse Transcriptase—Associated Ribonuclease H Activity,” Biology 1 (2012): 521–541. A. K. Singh, A. Kumar, S. Arora, et al., “Current Insights and Molecular Docking Studies of HIV‐1 Reverse Transcriptase Inhibitors,” Chemical Biology & Drug Design 103 (2024): e14372. R. Srivastava, S. K. Gupta, F. Naaz, et al., “Exploring Antiviral Potency of N‐1 Substituted Pyrimidines Against HIV‐1 and Other DNA/RNA Viruses: Design, Synthesis, Characterization, ADMET Analysis, Docking, Molecular Dynamics and Biological Activity,” Computational Biology and Chemistry 106 (2023): 107910. Y. Wang, A. Wang, J. Wang, X. Wu, Y. Sun, and Y. Wu, “Me‐Better Drug Design Based on Nevirapine and Mechanism of Molecular Interactions With Y188C Mutant HIV‐1 Reverse Transcriptase,” Molecules 27 (2022): 7348. C. Xu, Y. Xin, M. Chen, et al., “Discovery, Synthesis, and Optimization of an N‐Alkoxy Indolylacetamide Against HIV‐1 Carrying NNRTI‐Resistant Mutations From the Isatis indigotica Root,” European Journal of Medicinal Chemistry 189 (2020): 112071. P. Decha, P. Intharathep, T. Udommaneethanakit, et al., “Theoretical Studies on the Molecular Basis of HIV‐1RT/NNRTIs Interactions,” Journal of Enzyme Inhibition and Medicinal Chemistry 26 (2011): 29–36. D. Kang, D. Feng, Y. Sun, et al., “Structure‐Based Bioisosterism Yields HIV‐1 NNRTIs With Improved Drug‐Resistance Profiles and Favorable Pharmacokinetic Properties,” Journal of Medicinal Chemistry 63 (2020): 4837–4848. X. Jiang, J. Yu, Z. Zhou, et al., “Molecular Design Opportunities Presented by Solvent‐Exposed Regions of Target Proteins,” Medicinal Research Reviews 39 (2019): 2194–2238. X. Jiang, B. Huang, F. A. Olotu, et al., “Exploiting the Tolerant Region I of the Non‐Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket. Part 2: Discovery of Diarylpyrimidine Derivatives as Potent HIV‐1 NNRTIs With High Fsp3 Values and Favorable Drug‐Like Properties,” European Journal of Medicinal Chemistry 213 (2021): 113051. L. Ding, C. Pannecouque, E. De Clercq, C. Zhuang, and F.‐E. Chen, “Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment‐Based Replacement Strategy: From Biphenyl‐DAPYs to Heteroaromatic‐Biphenyl‐DAPYs,” Journal of Medicinal Chemistry 64 (2021): 10297–10311. R. Meleddu, A. Corona, S. Distinto, et al., “Exploring New Scaffolds for the Dual Inhibition of HIV‐1 RT Polymerase and Ribonuclease Associated Functions,” Molecules 26 (2021): 3821, https://doi.org/10.3390/molecules26133821. R. Meleddu, S. Distinto, A. Corona, et al., “Isatin Thiazoline Hybrids as Dual Inhibitors of HIV‐1 Reverse Transcriptase,” Journal of Enzyme Inhibition and Medicinal Chemistry 32 (2017): 130–136. R. Meleddu, S. Distinto, A. Corona, et al., “(3Z)‐3‐(2‐[4‐(aryl)‐1,3‐Thiazol‐2‐Yl]hydrazin‐1‐Ylidene)‐2,3‐Dihydro‐1H‐Indol‐2‐One Derivatives as Dual Inhibitors of HIV‐1 Reverse Transcriptase,” European Journal of Medicinal Chemistry 93 (2015): 452–460. A. Bielenica, G. Sanna, S. Madeddu, et al., “New Thiourea and 1,3‐Thiazolidin‐4‐One Derivatives Effective on the HIV‐1 Virus,” Chemical Biology & Drug Design 90 (2017): 883–891. Z. Xu, J. Guo, Y. Yang, et al., “2,4,5‐Trisubstituted Thiazole Derivatives as HIV‐1 NNRTIs Effective on Both Wild‐Type and Mutant HIV‐1 Reverse Transcriptase: Optimization of the Substitution of positions 4 and 5,” European Journal of Medicinal Chemistry 123 (2016): 309–316. A. Rauf, M. K. Kashif, B. A. Saeed, N. A. Al‐Masoudi, and S. Hameed, “Synthesis, Anti‐HIV Activity, Molecular Modeling Study and QSAR of New Designed 2‐(2‐Arylidenehydrazinyl)‐4‐Arylthiazoles,” Journal of Molecular Structure 1198 (2019): 126866. R. Gawali, J. Trivedi, S. Bhansali, R. Bhosale, D. Sarkar, and D. Mitra, “Design, Synthesis, Docking Studies and Biological Screening of 2‐Thiazolyl Substituted ‐2,3‐Dihydro‐1H‐Naphtho[1,2‐e][1,3]oxazines as Potent HIV‐1 Reverse Transcriptase Inhibitors,” European Journal of Medicinal Chemistry 157 (2018): 310–319. K.‐X. Zhao, Y.‐Y. Zhang, J.‐S. Wang, et al., “Design, Synthesis and Biological Evaluation of Thiazolo[3, 2‐a]Pyrimidine Derivatives as Novel RNase H Inhibitors,” Bioorganic Chemistry 148 (2024): 107495. R. P. D. Bank, n.d., “RCSB PDB ‐ 3LP2: HIV‐1 Reverse Transcriptase With Inhibitor.” accessed August 27, 2025, https://www.rcsb.org/structure/3LP2. A. L. Hopkins, J. Ren, R. M. Esnouf, et al., “Complexes of HIV‐1 Reverse Transcriptase With Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non‐Nucleoside Inhibitors,” Journal of Medicinal Chemistry 39 (1996): 1589–1600. R. P. D. Bank, n.d., “RCSB PDB ‐ 2ZD1: Crystal Structure of HIV‐1 Reverse Transcriptase (RT) in Complex With TMC278 (Rilpivirine), a Non‐Nucleoside RT Inhibitor.” accessed August 27, 2025, https://www.rcsb.org/structure/2ZD1. K. Das, J. D. Bauman, A. D. Clark, et al., “High‐Resolution Structures of HIV‐1 Reverse Transcriptase/TMC278 Complexes: Strategic Flexibility Explains Potency Against Resistance Mutations,” Proceedings of the National Academy of Sciences 105 (2008): 1466–1471. R. Suryawanshi, S. Jadhav, N. Makwana, et al., “Evaluation of 4‐Thiazolidinone Derivatives as Potential Reverse Transcriptase Inhibitors Against HIV‐1 Drug Resistant Strains,” Bioorganic Chemistry 71 (2017): 211–218. K. Daipule, N. S. Goud, A. Sethi, S. Gurrapu, E. Mamidala, and M. Alvala, “Synthesis, Molecular Docking Simulation, and Biological Evaluation Studies of Novel Amide and Ether Conjugates of 2,3‐Diaryl‐1,3‐Thiazolidin‐4‐Ones,” Journal of Heterocyclic Chemistry 57 (2020): 774–790. J. Balzarini, B. Orzeszko, J. K. Maurin, and A. Orzeszko, “Synthesis and Anti‐HIV Studies of 2‐Adamantyl‐Substituted ThiazolidIn‐4‐Ones,” European Journal of Medicinal Chemistry 42 (2007): 993–1003. R. S. Bahare, S. Ganguly, K. Choowongkomon, and S. Seetaha, “Synthesis, HIV‐1 RT Inhibitory, Antibacterial, Antifungal and Binding Mode Studies of Some Novel N‐Substituted 5‐Benzylidine‐2,4‐Thiazolidinediones,” DARU Journal of Pharmaceutical Sciences 23 (2015): 6. S. Ganguly and R. S. Bahare, “Molecular Docking Studies of Novel Thiazolidinedione Analogs as HIV‐1‐RT Inhibitors,” Medicinal Chemistry Research 22 (2013): 3350–3363. R. S. Bahare and S. Ganguly, “Comparative Molecular Docking Studies of Novel 3, 5‐Disubstituted Thiazolidinedione Analogs as HIV‐1‐RT Inhibitors,” Medicinal Chemistry Research 23 (2014): 1300–1308. M. Vanangamudi, S. Palaniappan, M. K. Kathiravan, and V. Namasivayam, “Strategies in the Design and Development of Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),” Viruses 15 (2023): 1992. D. Kang, F. Da, T. Ginex, et al., “Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine‐Substituted Thiophene[3,2‐d]pyrimidine Derivatives as Potent HIV‐1 NNRTIs,” Acta Pharmaceutica Sinica B 10 (2020): 878–894. J. A. Ippolito, H. Niu, N. Bertoletti, et al., “Covalent Inhibition of Wild‐Type HIV‐1 Reverse Transcriptase Using a Fluorosulfate Warhead,” ACS Medicinal Chemistry Letters 12 (2021): 249–255. K. M. Frey, D. E. Puleo, K. A. Spasov, M. Bollini, W. L. Jorgensen, and K. S. Anderson, “Structure‐Based Evaluation of Non‐Nucleoside Inhibitors With Improved Potency and Solubility That Target HIV Reverse Transcriptase Variants,” Journal of Medicinal Chemistry 58 (2015): 2737–2745. R. K. Raju, N. A. Burton, and I. H. Hillier, “Modelling the Binding of HIV‐Reverse Transcriptase and Nevirapine: An Assessment of Quantum Mechanical and Force Field Approaches and Predictions of the Effect of Mutations on Binding,” Physical Chemistry Chemical Physics 12, no. 26 (2010): 7117, https://doi.org/10.1039/c001384f. N. Fan, S. Zhang, T. Sheng, et al., “Docking Field‐Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV‐1 Reverse Transcriptase,” Chemical Biology & Drug Design 91, no. 2 (2017): 398–407, https://doi.org/10.1111/cbdd.13086. M. Camci and N. Karali, “Bioisosterism: 1,2,4‐Oxadiazole Rings,” ChemMedChem 18 (2023): e202200638. L. G. C. de Moraes, T. B. Santos, and D. R. da Rocha, “Molecular Hybridization of Naphthoquinones and Thiazoles: A Promising Strategy for Anticancer Drug Discovery,” Pharmaceuticals 18 (2025): 1887. A. K. Gao, T. B. Chen, V. L. Kouznetsova, and I. F. Tsigelny, “Machine‐Learning‐Based Virtual Screening and Ligand Docking Identify Potent HIV‐1 Protease Inhibitors,” Artificial Intelligence Chemistry 1 (2023): 100014. H. Uslu, B. Das, H. A. Dagdogen, et al., “Discovery of New Anti‐HIV Candidate Molecules With an AI‐Based Multi‐Stage System Approach Using Molecular Docking and ADME Predictions,” Chemometrics and Intelligent Laboratory Systems 267 (2025): 105543. L. M. Goulart, D. O. D. Senta, D. L. Andrade, and F. S. Kremer, “Integrated Virtual Screening and Molecular Dynamics Reveal Novel Maraviroc Analogues as Optimized CCR5 Entry Inhibitors for HIV‐1,” Journal of Molecular Graphics and Modelling 148 (2026): 109521. M. Azzouzi, S. E. E. Hadad, O. Azougagh, et al., “Synthesis, Characterization, and Antiviral Evaluation of New Chalcone‐Based Imidazo[1,2‐a]pyridine Derivatives: Insights From In Vitro and, In Silico, Anti‐HIV Studies,” Bioorganic Chemistry 154 (2025): 108102. M. Azzouzi, A. A. Ouchaoui, O. Azougagh, et al., “Synthesis, Crystal Structure, and Antiviral Evaluation of New Imidazopyridine‐Schiff Base Derivatives: In Vitro and In Silico Anti‐HIV Studies,” RSC Advances 14 (2024): 36902–36918. R. Minickaitė, B. Grybaitė, R. Vaickelionienė, et al., “Synthesis of Novel Aminothiazole Derivatives as Promising Antiviral, Antioxidant and Antibacterial Candidates,” International Journal of Molecular Sciences 23 (2022): 7688. R. Lesyk, “Drug Design: 4‐Thiazolidinones Applications. Part 2. Pharmacological Profiles,” Journal of Medical Science 89 (2020): e407. W. Liman, N. A. Lahcen, M. Oubahmane, et al., “Hybrid Molecules as Potential Drugs for the Treatment of HIV: Design and Applications,” Pharmaceuticals 15 (2022): 1092. C. Tratrat, A. Petrou, M. Fesatidou, M. Haroun, M. Chohan, and A. Geronikaki, “Rational Design, Synthesis, and Biological Evaluation of Novel Thiazole/Thiazolidinones Multitarget Anti‐Human Immunodeficiency Virus Molecules,” Pharmaceuticals 18 (2025): 298. Y. Chen, Y. Tian, Y. Gao, et al., “In Silico Design of Novel HIV‐1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4‐d]pyrimidines,” Frontiers in Chemistry 8 (2020): 164, https://doi.org/10.3389/fchem.2020.00164. S. K. Thompson, K. H. M. Murthy, B. Zhao, et al., “Rational Design, Synthesis, and Crystallographic Analysis of a Hydroxyethylene‐Based HIV‐1 Protease Inhibitor Containing a Heterocyclic P1’‐P2’ Amide Bond Isostere,” Journal of Medicinal Chemistry 37 (1994): 3100–3107. S. Duan and S. Liu, “Targeting NK Cells for HIV‐1 Treatment and Reservoir Clearance,” Frontiers in Immunology 13 (2022): 842746, https://doi.org/10.3389/fimmu.2022.842746. M. Weichseldorfer, M. Reitz, and O. S. Latinovic, “Past HIV‐1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV‐1 Patients,” Pharmaceutics 13 (2021): 1798. I. Sánchez‐Cerrillo, M. Agudo‐Lera, O. Popova, et al., “Combined Dendritic Cell and Anti‐TIGIT Immunotherapy Potentiates Adaptive NK Cells Against HIV‐1,” EMBO Molecular Medicine 17 (2025): 1756–1793. L. C. Ndhlovu, L. B. Giron, J. Galinskas, et al., “Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV,” Journal of Infectious Diseases 232 (2025): 1067–1077. G. Siracusano and L. Lopalco, “Immunotherapy With Cell‐Based Biological Drugs to Cure HIV‐1 Infection,” Cells 11 (2022): 77. |
| Grant Information: | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco; Conseil National de la Recherche Scientifique |
| Contributed Indexing: | Keywords: antiviral therapy; antivirals; chemistry; drug design; pharmacodynamic; pharmacology |
| Substance Nomenclature: | EC 2.7.7.49 (HIV Reverse Transcriptase) 0 (Reverse Transcriptase Inhibitors) EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1) 0 (Thiazoles) 0 (Thiazolidines) 0 (Anti-HIV Agents) |
| Entry Date(s): | Date Created: 20260930 Date Completed: 20261001 Latest Revision: 20260930 |
| Update Code: | 20261001 |
| DOI: | 10.1002/cmdc.70494 |
| PMID: | 42816789 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!